Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
Information source: Asociación para Evitar la Ceguera en México
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Vogt Koyanagi Harada Disease; Serpiginous Choroiditis; Multifocal Choroiditis
Intervention: Bevacizumab (Drug); Intravitreal Injection of Bevacizumab (Procedure)
Phase: Phase 3
Status: Completed
Sponsored by: Asociación para Evitar la Ceguera en México Official(s) and/or principal investigator(s): Veronica Kon-Jara, MD, Principal Investigator, Affiliation: Asociación para Evitar la Ceguera en México LuzElena Concha-Del Rio, MD, Study Chair, Affiliation: Asociación para Evitar la Ceguera en México
Summary
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to
intraocular inflammation. We injected a single injection of Bevacizumab (2. 5 mg/0. 1 ml) and
evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence
Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous
Choroidopathy and 1 patient with Multifocal Choroiditis.
Clinical Details
Official title: Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Best corrected visual acuityRetinal thickness by OCT Leakage in Fluorescein angiogram
Eligibility
Minimum age: 25 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical Diagnose
- Patient Consent
- Chronic stage of inflammation
Exclusion Criteria:
- only eye
- age lower than 30 yo.
- Systemic condition
Locations and Contacts
Asociacion para Evitar la Ceguera en Mexico, Mexico, Distrito Federal 04030, Mexico
Additional Information
Starting date: August 2006
Last updated: December 1, 2006
|